• Develop low-cost, orally available drugs for the treatment of dengue having a dosing regimen that allows for optimal patient compliance

• Partner with the best academic and clinical dengue scientists

• Discover small molecule compounds through “smart” strategies targeting hitherto undrugged serotype-conserved parts of dengue and host cell targets

• Combination of biophysical screening and structural biology techniques, targeting conserved regions of viral proteins , with HTS-directed design around active fragments, to rapidly develop SAR and optimise hit to leads

• Compound optimisation will be based on antiviral activity against all four serotypes and we aim to have at least one preclinical candidate within three years

• Our initial focus are Dengue viral targets and we are exploring the utility of host cell targets to treat this disease. Additionally, we are exploring other discovery approaches